SV2009003429A - Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica - Google Patents

Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica

Info

Publication number
SV2009003429A
SV2009003429A SV2009003429A SV2009003429A SV2009003429A SV 2009003429 A SV2009003429 A SV 2009003429A SV 2009003429 A SV2009003429 A SV 2009003429A SV 2009003429 A SV2009003429 A SV 2009003429A SV 2009003429 A SV2009003429 A SV 2009003429A
Authority
SV
El Salvador
Prior art keywords
alquinil
therapeutics
derivatives
preparation
application
Prior art date
Application number
SV2009003429A
Other languages
English (en)
Inventor
Antoine Alam
Sandrine Biscarrat
Isabelle Blanc
Francoise Bono
Oliver Duclos
Cort Gary Mc
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of SV2009003429A publication Critical patent/SV2009003429A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

LA INVENCIÓN SE REFIERE A LOS DERIVADOS DE 7-ALQUINIL-1,8-NAFTIRIDONAS DE FÓRMULA GENERAL (!), EN LA QUE RI, RA, R3 Y R4 SON TALES COMO SE DEFINEN EN LA DESCRIPCIÓN. PROCEDIMIENTO DE PREPARACIÓN Y APLICACIÓN EN TERAPÉUTICA
SV2009003429A 2007-06-13 2009-12-03 Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica SV2009003429A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0704192A FR2917412B1 (fr) 2007-06-13 2007-06-13 Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
SV2009003429A true SV2009003429A (es) 2010-02-05

Family

ID=38870275

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003429A SV2009003429A (es) 2007-06-13 2009-12-03 Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica

Country Status (44)

Country Link
US (1) US8470847B2 (es)
EP (1) EP2158201B1 (es)
JP (1) JP5343072B2 (es)
KR (1) KR101517636B1 (es)
CN (1) CN101679427B (es)
AP (1) AP2590A (es)
AR (1) AR066954A1 (es)
AT (1) ATE505469T1 (es)
AU (1) AU2008274099B2 (es)
CA (1) CA2690337C (es)
CL (1) CL2008001775A1 (es)
CO (1) CO6150150A2 (es)
CR (1) CR11157A (es)
CY (1) CY1111631T1 (es)
DE (1) DE602008006188D1 (es)
DK (1) DK2158201T3 (es)
DO (1) DOP2009000264A (es)
EA (1) EA016939B1 (es)
EC (1) ECSP099791A (es)
ES (1) ES2365073T3 (es)
FR (1) FR2917412B1 (es)
GT (1) GT200900309A (es)
HK (1) HK1141790A1 (es)
HN (1) HN2009003402A (es)
HR (1) HRP20110515T1 (es)
IL (1) IL202640A (es)
JO (1) JO2682B1 (es)
MA (1) MA31567B1 (es)
ME (1) ME00961B (es)
MX (1) MX2009013515A (es)
MY (1) MY157754A (es)
NI (1) NI200900211A (es)
NZ (1) NZ581839A (es)
PA (1) PA8781701A1 (es)
PE (1) PE20090307A1 (es)
PL (1) PL2158201T3 (es)
PT (1) PT2158201E (es)
SI (1) SI2158201T1 (es)
SV (1) SV2009003429A (es)
TN (1) TN2009000483A1 (es)
TW (1) TWI405762B (es)
UA (1) UA96994C2 (es)
UY (1) UY31152A1 (es)
WO (1) WO2009007535A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2917413B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
FR2965263A1 (fr) 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
JP5748210B2 (ja) * 2011-05-26 2015-07-15 日本化薬株式会社 複素環化合物の製造方法
US9376432B2 (en) * 2012-07-17 2016-06-28 Sanofi Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma
CN108558869B (zh) * 2018-05-10 2019-04-09 西安培华学院 用于治疗肝癌的化合物及其制剂
CN110981869A (zh) * 2019-12-10 2020-04-10 天津科技大学 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225555A1 (en) * 1995-08-02 1997-02-13 Chiroscience Limited Quinolones and their therapeutic use
CA2285352A1 (en) * 1998-01-29 1999-08-05 Suntory Limited 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase iv inhibitory activity
AU2002257459B2 (en) * 2001-05-24 2006-12-14 Merck Frosst Canada Ltd 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
EP1761539A1 (en) 2004-06-02 2007-03-14 Takeda Pharmaceutical Company Limited Indole derivative and use for treatment of cancer
FR2917413B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
NI200900211A (es) 2010-07-15
UY31152A1 (es) 2009-01-30
UA96994C2 (ru) 2011-12-26
EA016939B1 (ru) 2012-08-30
JP5343072B2 (ja) 2013-11-13
AU2008274099A1 (en) 2009-01-15
AP2010005099A0 (en) 2010-02-28
US8470847B2 (en) 2013-06-25
IL202640A0 (en) 2010-06-30
PE20090307A1 (es) 2009-04-20
DK2158201T3 (da) 2011-08-01
CY1111631T1 (el) 2015-10-07
TW200911802A (en) 2009-03-16
SI2158201T1 (sl) 2011-07-29
MA31567B1 (fr) 2010-08-02
WO2009007535A3 (fr) 2009-04-09
HN2009003402A (es) 2012-02-27
KR20100020000A (ko) 2010-02-19
CA2690337A1 (fr) 2009-01-15
BRPI0814035A2 (pt) 2020-08-04
JP2010529178A (ja) 2010-08-26
ES2365073T3 (es) 2011-09-21
DOP2009000264A (es) 2009-12-15
TWI405762B (zh) 2013-08-21
FR2917412A1 (fr) 2008-12-19
GT200900309A (es) 2012-01-26
ECSP099791A (es) 2010-01-29
CN101679427A (zh) 2010-03-24
DE602008006188D1 (de) 2011-05-26
AU2008274099B2 (en) 2013-05-16
FR2917412B1 (fr) 2009-08-21
NZ581839A (en) 2011-05-27
WO2009007535A2 (fr) 2009-01-15
CA2690337C (fr) 2015-08-11
CL2008001775A1 (es) 2009-09-25
HK1141790A1 (es) 2010-11-19
IL202640A (en) 2014-01-30
PL2158201T3 (pl) 2011-09-30
US20100144757A1 (en) 2010-06-10
ME00961B (me) 2012-06-20
CO6150150A2 (es) 2010-04-20
EA201070009A1 (ru) 2010-06-30
TN2009000483A1 (fr) 2011-03-31
EP2158201B1 (fr) 2011-04-13
MX2009013515A (es) 2010-01-27
ATE505469T1 (de) 2011-04-15
KR101517636B1 (ko) 2015-05-04
JO2682B1 (en) 2013-03-03
HRP20110515T1 (hr) 2011-08-31
AP2590A (en) 2013-02-04
CN101679427B (zh) 2013-02-20
PT2158201E (pt) 2011-07-05
CR11157A (es) 2010-03-23
MY157754A (en) 2016-07-15
EP2158201A2 (fr) 2010-03-03
PA8781701A1 (es) 2009-01-23
AR066954A1 (es) 2009-09-23

Similar Documents

Publication Publication Date Title
SV2009003429A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
UY31037A1 (es) Derivados de triazolopiridin-carboxamidas, su preparacion y su aplicacion en terapeutica
HN2011000076A (es) Derivados de piridino-piridinonas, su preparacion.
UY33427A (es) Derivados de carbamatos de hexafluoroisopropilo, su preparacion y su aplicacion en terapeutica
UY31032A1 (es) Derivados de triazolopiridin-carboxamidas y triazolopirimidin-carboxinamidas, su preparacion y su aplicacion en terapeutica
SV2010003472A (es) Compuestos de pirazol
CU20110204A7 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
CR11427A (es) 2-fluoro-2 - desoxitetrahidrouridinas como inhibidores de citidina desaminasa
ECSP10010722A (es) Compuestos orgánicos
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
ECSP11011340A (es) Nuevos derivados de benzotiadiazepinas, su procedimiento de preparación y composiciones farmacéuticas que los contienen
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
HN2012000261A (es) Derivados de 5-fluoro-2-oxopirimidina-1(2h)-carboxilato
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
HN2010001537A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
NI201000023A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica.
UY31036A1 (es) Derivados de triazolopiridina-carboxamidas, su preparacion y su aplicacionen terapeutica
CR20110701A (es) Derivados de pirazoles, su preparacion y su aplicacion terapeutica.
NI201000089A (es) Derivados de pirazol como inhibidores de 5-lo.
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
CO6501125A2 (es) Nuevos derivados (heterociclico-tetrahidro-piridin)-(piperazinil)-1- alcanona y (heterociclo-dhidro-pirrolidin)-(piperazinil)-1-alcanona y su utilización como inhibidores de p75
GT201200066A (es) Nuevos derivados dihidro-oxazolobenzodiazepinonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY32154A (es) Derivados de isoquinolinona, procesos para su preparacion, composiciones farmaceuticas que los contiene y su uso en terapia
UY29691A1 (es) Derivados de n-(arilalquil)-1h-pirrolopiridin-2-carboxamidas, su preparación y su aplicación en terapéutica.

Legal Events

Date Code Title Description
FD Lapse